Start Printed Page 23776
Under Secretary of Defense for Personnel and Readiness, Department of Defense.
Notice of Federal Advisory Committee meeting.
The Department of Defense (DoD) is publishing this notice to announce that the following Federal Advisory Committee meeting of the Uniform Formulary Beneficiary Advisory Panel will take place.
Open to the public Wednesday, June 26, 2019, from 9:00 a.m. to 12:00 p.m.
The address of the open meeting is the Naval Heritage Center Theater, 701 Pennsylvania Avenue NW, Washington, DC 20004.
Start Further Info
FOR FURTHER INFORMATION CONTACT:
Colonel Paul J. Hoerner, USAF, 703-681-2890 (Voice), None (Facsimile), firstname.lastname@example.org (Email). Mailing address is 7700 Arlington Boulevard, Suite 5101, Falls Church, VA 22042-5101. Website: https://health.mil/bap. The most up-to-date changes to the meeting agenda can be found on the website.
End Further Info
Start Supplemental Information
This meeting is being held under the provisions of the Federal Advisory Committee Act (FACA) of 1972 (5 U.S.C., Appendix, as amended), the Government in the Sunshine Act of 1976 (5 U.S.C. 552b, as amended), and 41 CFR 102-3.140 and 102-3.150.
The Panel will review and comment on recommendations made to the Director of the Defense Health Agency, by the Pharmacy and Therapeutics Committee, regarding the Uniform Formulary.
Purpose of the Meeting: The Department of Defense (DoD) is publishing this notice to announce that the following Federal Advisory Committee meeting of the Uniform Formulary Beneficiary Advisory Panel will take place.
2. Welcome and Opening Remarks.
3. Scheduled Therapeutic Class Reviews (Comments will follow each agenda item).
a. Proton Pump Inhibitors—Alternate Dosage Forms.
b. Proton Pump Inhibitors—Capsules and Tablets.
c. Pulmonary Arterial Hypertension—Endothelin Receptor Antagonists.
d. Pulmonary Arterial Hypertension—Prostacyclin Nebulized Therapy.
e. Pulmonary Arterial Hypertension—Prostacyclin Oral Therapy.
f. Pulmonary Arterial Hypertension—Soluble Guanylate Cyclase Stimulator.
4. Newly Approved Drugs Review.
5. Pertinent Utilization Management Issues.
6. Panel Discussions and Vote.
Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and 41 Code of Federal Regulations (CFR) 102-3.140 through 102-3.165, and the availability of space, this meeting is open to the public. Seating is limited and will be provided only to the first 220 people signing-in. All persons must sign-in legibly.
Written Statements: Pursuant to 41 CFR 102-3.140, the public or interested organizations may submit written statements to the membership of the Panel about its mission and/or the agenda to be addressed in this public meeting. Written statements should be submitted to the Panel's Designated Federal Officer (DFO). The DFO's contact information can be obtained previously in this announcement. Written comments or statements must be received by the committee DFO at least five (5) business days prior to the meeting so that they may be made available to the Panel for its consideration prior to the meeting. The DFO will review all submitted written statements and provide copies to all the committee members.
End Supplemental Information
Dated: May 17, 2019.
Aaron T. Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2019-10740 Filed 5-22-19; 8:45 am]
BILLING CODE 5001-06-P